G. Morgan

发表

Aspirin for the second hundred years: new uses for an old drug.

H. Vainio, G. Morgan, Harri Vainio, 1997, Pharmacology & toxicology.

Non-steroidal anti-inflammatory drugs and the chemoprevention of gastrointestinal cancers.

H. Vainio, G. Morgan, 1998, Scandinavian journal of gastroenterology.

Aspirin chemoprevention of cancer: Messages for health educators

G. Morgan, 1996 .

An international evaluation of the cancer-preventive potential of nonsteroidal anti-inflammatory drugs.

P. Kleihues, H. Vainio, G. Morgan, 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Nonsteroidal antiinflammatory drugs and colorectal cancer

G. Morgan, 1995, Cancer.

Aspirin and colorectal cancer?

G. Morgan, 2004, European journal of public health.

Aspirin, salicylates and cancer: report of a meeting at the Royal Society of Medicine, London, 23 November 2010

J. Cuzick, P. Rothwell, J. Burn, 2011, Ecancermedicalscience.

A quantitative illustration of the public health potential of aspirin.

G. Morgan, 2003, Medical hypotheses.

Non-steroidal anti-inflammatory drugs and the chemoprevention of colorectal and oesophageal cancers.

G. Morgan, 1996, Gut.

Aspirin and the risk of digestive cancers.

G. Morgan, 1995, Archives of internal medicine.

NSAIDs and the chemoprevention of oesophageal cancer

J. Williams, G. Morgan, 1994, The Lancet.

Colorectal cancer protection by endoscopic and NSAID combination.

G. Morgan, 1996, Archives of internal medicine.

Meeting Report An International Evaluation of the Cancer-Preventive Potential of Nonsteroidal Anti-inflammatory Drugs 1

P. Kleihues, H. Vainio, G. Morgan, 1997 .

Tumouricidal effect of indomethacin in the esophagus.

J. Williams, G. Morgan, 1993, Postgraduate medical journal.

Nsaids, free radicals, and reflux esophagitis

G. Morgan, 1996, Digestive Diseases and Sciences.

Inflammatory mediators in the oesophagus.

J. Williams, G. Morgan, 1994, Gut.

Prostaglandins as mediators of lower esophageal sphincter dysfunction in esophagitis.

J. Williams, G. Morgan, 1993, Gastroenterology.

NSAIDs and the chemoprevention of colon and oesophageal cancer.

G. Morgan, 1995, Gut.

Non-steroidal anti-inflammatory drugs and chemoprevention of cancer.

H. Vainio, G. Morgan, 2000, Annales chirurgiae et gynaecologiae.

Aspirin chemoprevention of colorectal and oesophageal cancers. An overview of the literature and homeopathic explanation.

G. Morgan, 1996, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Barrett's oesophagus, oesophageal cancer and colon cancer: an explanation of the association and cancer chemopreventive potential of non-steroidal anti-inflammatory drugs.

H. Vainio, G. Morgan, 1998, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Barriers to Small Molecule Drug Discovery for Systemic Amyloidosis

G. Morgan, G. Morgan, 2021, Molecules.

Might salicylate exert benefits against childhood cancer?

G. Morgan, J. Johnsen, 2010, Ecancermedicalscience.

Potential contribution of aspirin to cancer control programmes

G. Morgan, 2008, Ecancermedicalscience.

Therapeutic potential of aspirin in cancer of the colon.

J. Williams, G. Morgan, 1993, BMJ.

The cancer-preventive potential of Panax ginseng: a review of human and experimental evidence

Harri Vainio, Hai-rim Shin, H. Vainio, 2000, Cancer Causes & Control.

Aspirin and risk of fatal colon cancer.

J. Williams, G. Morgan, 1993, Postgraduate medical journal.

Should aspirin be used to counteract 'salicylate deficiency'?

G. Morgan, 2003, Pharmacology & toxicology.

Deleterious effects of prostaglandin E2 in oesophageal carcinogenesis.

G. Morgan, 1997, Medical hypotheses.

NSAIDs, Barrett's oesophagus and adenocarcinoma prevention.

H. Vainio, G. Morgan, 1997, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Mechanisms of aspirin chemoprevention of colorectal cancer

H. Vainio, G. Morgan, 1999, European Journal of Drug Metabolism and Pharmacokinetics.

WHO should consider the benefits of aspirin prophylaxis in middle age?

G. Morgan, 2009, American journal of hypertension.

A comparison of the pathophysiological arachidonic acid metabolism in the gastric and oesophageal mucosa

John G. Williams, G. Morgan, 1995 .

Deleterious effects of prostaglandin E2 in reflux oesophagitis.

G. Morgan, 1996, Medical hypotheses.

Cyclo-oxygenase 2 and breast cancer prevention

H. Vainio, G. Morgan, 1998, BMJ.